Actinium Pharmaceuticals to Present at the Biotech Showcase™ 2013

Actinium Pharmaceuticals will present clinical progress of its lead drug candidates to investors and biotech industry executives for the first time as a public company

News provided by

Actinium Pharmaceuticals, Inc.

Jan 04, 2013, 05:55 ET

NEW YORK, Jan. 4, 2013 /PRNewswire/ -- Actinium Pharmaceuticals, Inc. (OTCBB: CTVN) today announced that Jack Talley, the company's President and Chief Executive Officer, will be presenting at the Biotech Showcase in San Francisco on Monday, January 7, 2013 at 11:45 AM Pacific Time.

The presentation will include an overview of Actinium's clinical stage drug candidates Actimab-A and Iomab-B for treatment of hematological cancers and discussion of its proprietary patented alpha particle immunotherapy technology (APIT).

The Biotech Showcase is being held at the Parc 55 Wyndham Union Square Hotel in San Francisco and it provides private and public life science companies the opportunity to present to an audience of investors and business development executives.

About Actinium Pharmaceuticals

Actinium Pharmaceuticals, Inc. is a New York, New York based biopharmaceutical company that develops innovative alpha particle immunotherapeutics based on its proprietary platform for the therapeutic utilization of alpha particle emitting actinium-225 and bismuth-213 isotopes in association with monoclonal antibodies. The Company also develops other radiopharmaceuticals for select applications.

For more information:

Visit our web site www.actiniumpharmaceuticals.com or contact:

Jack Talley, CEO
Actinium Pharmaceuticals Inc.
Tel: (646) 459-4201
E-mail: [email protected]

Investors:
Jeff Ramson
ProActive Capital Group, LLC
Tel: (646) 863-6341
E-mail: [email protected]
www.proactivecrg.com

Media:
Dennis S. Dobson Jr., 203-258-0159
Tel: (203) 258-0150
Email: [email protected]
www.dobsonmediagroup.com

Forward-Looking Statement for Actinium Pharmaceuticals, Inc.

This news release contains "forward-looking statements" as that term is defined in the Private Securities Litigation Reform Act of 1995. These statements are based on management's current expectations and involve risks and uncertainties, which may cause results to differ materially from those set forth in the statements. The forward-looking statements may include statements regarding product development, product potential, or financial performance. No forward-looking statement can be guaranteed and actual results may differ materially from those projected. Actinium Pharmaceuticals undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events, or otherwise.

SOURCE Actinium Pharmaceuticals, Inc.